1-Hydroxy-2(1<i>H</i>)-pyridinone-Based Chelators with Potential Catechol <i>O</i>-Methyl Transferase Inhibition and Neurorescue Dual Action against Parkinson’s Disease
Joseph C. J. Bergin,
Kean Kan Tan,
Anya K. Nelson,
Cristina-Andreea Amarandei,
Véronique Hubscher-Bruder,
Jérémy Brandel,
Varvara Voinarovska,
Annick Dejaegere,
Roland H. Stote,
David Tétard
Affiliations
Joseph C. J. Bergin
Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
Kean Kan Tan
Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
Anya K. Nelson
Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
Cristina-Andreea Amarandei
Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France
Véronique Hubscher-Bruder
Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France
Jérémy Brandel
Université de Strasbourg, CNRS, IPHC UMR 7178, F-67000 Strasbourg, France
Varvara Voinarovska
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de La Santé et de La Recherche Médicale (INSERM), U1258/Centre National de Recherche Scientifique (CNRS), UMR7104/Université de Strasbourg, 67404 Illkirch, France
Annick Dejaegere
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de La Santé et de La Recherche Médicale (INSERM), U1258/Centre National de Recherche Scientifique (CNRS), UMR7104/Université de Strasbourg, 67404 Illkirch, France
Roland H. Stote
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Institut National de La Santé et de La Recherche Médicale (INSERM), U1258/Centre National de Recherche Scientifique (CNRS), UMR7104/Université de Strasbourg, 67404 Illkirch, France
David Tétard
Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne NE1 8ST, UK
Two analogues of tolcapone where the nitrocatechol group has been replaced by a 1-hydroxy-2(1H)-pyridinone have been designed and synthesised. These compounds are expected to have a dual mode of action both beneficial against Parkinson’s disease: they are designed to be inhibitors of catechol O-methyl transferase, which contribute to the reduction of dopamine in the brain, and to protect neurons against oxidative damage. To assess whether these compounds are worthy of biological assessment to demonstrate these effects, measurement of their pKa and stability constants for Fe(III), in silico modelling of their potential to inhibit COMT and blood–brain barrier scoring were performed. These results demonstrate that the compounds may indeed have the desired properties, indicating they are indeed promising candidates for further evaluation.